LIVINGSTON, N.J. and MUNICH, Sept. 26, 2018 /PRNewswire/ -- Nanion announced today that Charles River Laboratories has purchased two SyncroPatch 384PE high-throughput patch clamp instruments. This purchase reflects an investment in screening technologies and assay development, while accommodating the rising demand in contract service for globally shared clients. The instruments will be delivered to Charles River (Cleveland site; former ChanTest) in November of this year and will be used for various ion channel screening & profiling services, including cardiac safety screening, efficacy, and SAR studies.
Dr. Jessica Brimecombe Site Director Charles River Cleveland comments: "We are excited to have acquired this technology for our services. Coupling our strength and expertise in the ion channel and transporter assay fields with Nanion's state-of-the-art technology allows us to bring new options to our customers."
Andrea Brüggemann, CSO Nanion comments: "Charles River and Nanion Technologies have been successfully collaborating for many years and we are pleased that they have expressed their confidence in our technology through this purchase. I believe that the SyncroPatch 384PE will integrate seamlessly into Charles River Laboratories, where the flexibility of the instrument will help service their many diverse projects. We are looking forward to our continued collaboration and the new potential challenges it will bring."
About Nanion Technologies
Nanion Technologies is a leading provider of instrumentation for ion channel drug discovery and screening. Founded in 2002, Nanion has grown over the last 16 years to a company with over 100 employees worldwide. With headquarters in Munich, Germany, Nanion has subsidiaries in the USA, Denmark, Japan and China, as well as distribution partners in seven other countries. Nanion's team has developed and successfully established four generations of automated patch clamp instruments for sophisticated and high throughput applications in ion channel research and drug discovery (Port-a-Patch, Patchliner and SyncroPatch product families). Further product lines are for cardiotoxicity screening (CardioExcyte 96), for parallel bilayer recordings (Orbit family), and for parallel membrane transporter protein recordings (SURFE²R).
Dr. Andrea Brüggemann CSO Nanion Munich Germany Phone: +49 89 2190 95 - 066 Email: firstname.lastname@example.org
Rodolfo Haedo, SVP Nanion North America, Phone: +1 (862) 221-2790 Email: email@example.com
SOURCE Nanion Technologies